These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 32286656)

  • 1. Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.
    Tseng CW; Dudley RA; Chen R; Walensky RP
    JAMA Netw Open; 2020 Apr; 3(4):e202739. PubMed ID: 32286656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
    Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
    JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
    Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
    Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
    Polinski JM; Mohr PE; Johnson L
    Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
    Dusetzina SB; Keating NL
    J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
    JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis.
    Doshi JA; Hu T; Li P; Pettit AR; Yu X; Blum M
    Arthritis Care Res (Hoboken); 2016 Nov; 68(11):1624-1630. PubMed ID: 27014854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study.
    Li P; Hu T; Yu X; Chahin S; Dahodwala N; Blum M; Pettit AR; Doshi JA
    Health Serv Res; 2018 Aug; 53 Suppl 1(Suppl Suppl 1):2735-2757. PubMed ID: 28736929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.
    Erath A; Dusetzina SB
    JAMA Netw Open; 2020 Apr; 3(4):e203969. PubMed ID: 32338754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do Medicare Beneficiaries Living With HIV/AIDS Choose Prescription Drug Plans That Minimize Their Total Spending?
    Desmond KA; Rice TH; Leibowitz AA
    Inquiry; 2017 Jan; 54():46958017734032. PubMed ID: 28990452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
    Doshi JA; Li P; Huo H; Pettit AR; Kumar R; Weiss BM; Huntington SF
    Am J Manag Care; 2016 Mar; 22(4 Suppl):s78-86. PubMed ID: 27270157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-exposure prophylaxis for preventing acquisition of HIV: A cross-sectional study of patients, prescribers, uptake, and spending in the United States, 2015-2016.
    Chan SS; Chappel AR; Maddox KEJ; Hoover KW; Huang YA; Zhu W; Cohen SM; Klein PW; De Lew N
    PLoS Med; 2020 Apr; 17(4):e1003072. PubMed ID: 32275654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
    Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
    Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How Low-Income Subsidy Recipients Respond to Medicare Part D Cost Sharing.
    Stuart B; Hendrick FB; Xu J; Dougherty JS
    Health Serv Res; 2017 Jun; 52(3):1185-1206. PubMed ID: 27324201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The private health insurance choices of medicare beneficiaries: how much does price matter?
    Rice T; Jacobson G; Cubanski J; Neuman T
    Med Care Res Rev; 2014 Dec; 71(6):661-89. PubMed ID: 25371217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Medicare drug benefit: update on the low-income subsidy.
    Stahlman ME
    Issue Brief George Wash Univ Natl Health Policy Forum; 2009 Jul; (833):1-22. PubMed ID: 19685590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs.
    Hsu J; Fung V; Price M; Huang J; Brand R; Hui R; Fireman B; Newhouse JP
    JAMA; 2008 Apr; 299(16):1929-36. PubMed ID: 18430912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men.
    Drabo EF; Hay JW; Vardavas R; Wagner ZR; Sood N
    Clin Infect Dis; 2016 Dec; 63(11):1495-1504. PubMed ID: 27558571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coverage for hepatitis C drugs in Medicare Part D.
    Jung JK; Feldman R; Cheong C; Du P; Leslie D
    Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.